Earnings Feed
Start Free
Home/Filings/3/0000899243-20-003395
3//SEC Filing

ARCH Venture Partners IX, LLC 3

Accession 0000899243-20-003395

CIK 0001745999other
View on SEC.govCompany Profile

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 7:29 PM ET

Size

26.9 KB

Accession

0000899243-20-003395

Insider Transaction Report

Form 3
Period: 2020-02-05
Beam Therapeutics Inc.BEAM
ARCH Venture Partners IX Overage, L.P.
10% Owner
Holdings

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)
ARCH Venture Fund IX, L.P.
10% Owner
Holdings

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)
ARCH Venture Fund IX Overage, L.P.
10% Owner
Holdings

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)
ARCH Venture Partners IX, LLC
10% Owner
Holdings

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)
ARCH Venture Partners IX, L.P.
10% Owner
Holdings

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)
CRANDELL KEITH
10% Owner
Holdings

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)
BYBEE CLINTON
10% Owner
Holdings

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,336 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-1 Preferred Stock

    (indirect: See footnote)
    → Common Stock (1,338,000 underlying)

  • Series A-2 Preferred Stock

    (indirect: See footnote)
    → Common Stock (2,750,335 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)

  • Series B Preferred Stock

    (indirect: See footnote)
    → Common Stock (33,184 underlying)
Footnotes (3)
  • [F1]These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
  • [F2]Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the registrant, for no additional consideration. There is no expiration date for the Preferred Stock.
  • [F3]These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Documents

2 files

Issuer

Beam Therapeutics Inc.

CIK 0001745999

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001723174

Filing Metadata

Form type
3
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 7:29 PM ET
Size
26.9 KB
View on SEC.gov